Skip to main content

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

Terminated · Phase 2 · NCT05543252

Conditions: Parkinson's Disease

At a glance

Research payments reported, 2025
$899,812
U.S. investigators named
43
Sites paid
46
Planned or actual enrollment
428

About the trial

Sponsor
UCB Biopharma SRL
Tested
Minzasolmin (UCB0599) (drug)
Dates
Started 2022-08-29; completion 2025-03-25
Results posted
Yes

The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.

From ClinicalTrials.gov, last updated 2026-04-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

UCB SA reported $899,812 in research payments for this study in 2025 (56 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.